Published in J Clin Endocrinol Metab on November 07, 2006
Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome | NCT00679679
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol (2011) 3.02
Polycystic Ovary Syndrome. N Engl J Med (2016) 2.65
Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2013) 2.43
Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev (2012) 2.22
Challenges to the measurement of estradiol: an endocrine society position statement. J Clin Endocrinol Metab (2013) 2.11
Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 2.08
The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag (2009) 1.90
Correlations of free thyroid hormones measured by tandem mass spectrometry and immunoassay with thyroid-stimulating hormone across 4 patient populations. Clin Chem (2009) 1.79
Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry (2010) 1.73
Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab (2011) 1.71
Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. J Clin Endocrinol Metab (2010) 1.62
Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol (2011) 1.61
Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab (2014) 1.61
Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol (2008) 1.55
The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol (2011) 1.51
Identification of SOX3 as an XX male sex reversal gene in mice and humans. J Clin Invest (2010) 1.50
Correlation of serum androgens with anthropometric and metabolic indices in healthy, nonobese postmenopausal women. J Clin Endocrinol Metab (2010) 1.46
Testosterone is associated with erectile dysfunction: a cross-sectional study in Chinese men. PLoS One (2012) 1.46
Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older European men. Pain (2011) 1.41
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab (2010) 1.29
Sex steroid actions in male bone. Endocr Rev (2014) 1.26
Visually scoring hirsutism. Hum Reprod Update (2009) 1.21
Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab (2008) 1.18
Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril (2009) 1.10
Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab (2013) 1.10
Renaming PCOS--a two-state solution. J Clin Endocrinol Metab (2013) 1.08
Urinary concentrations of di(2-ethylhexyl) phthalate metabolites and serum reproductive hormones: pooled analysis of fertile and infertile men. J Androl (2011) 1.06
Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev (2015) 1.06
Research methodology: endocrinologic measurements in exercise science and sports medicine. J Athl Train (2008) 1.00
Endocrinology of the aging male. Best Pract Res Clin Endocrinol Metab (2011) 0.99
Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the framingham heart study. Diabetes Care (2011) 0.99
Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab (2009) 0.99
The use of hormonal therapy in "andropause": the pro side. Can Urol Assoc J (2008) 0.98
Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One (2011) 0.98
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male (2015) 0.97
Tandem mass spectrometry as a novel tool for elucidating pituitary-thyroid relationships. Thyroid (2008) 0.96
Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can (2008) 0.96
Testosterone concentrations in young pubertal and post-pubertal obese males. Clin Endocrinol (Oxf) (2013) 0.94
Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. Oncologist (2011) 0.94
Prospective association of serum androgens and sex hormone-binding globulin with subclinical cardiovascular disease in young adult women: the "Coronary Artery Risk Development in Young Adults" women's study. J Clin Endocrinol Metab (2010) 0.93
Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease. J Clin Endocrinol Metab (2008) 0.93
PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol (Oxf) (2011) 0.91
Challenges and improvements in testosterone and estradiol testing. Asian J Androl (2014) 0.91
Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods. Steroids (2008) 0.91
Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab (2009) 0.90
Digit ratios do not serve as anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome. Hum Reprod (2009) 0.90
Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PLoS One (2014) 0.90
Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor. FASEB J (2014) 0.89
Premenopausal serum androgens and breast cancer risk: a nested case-control study. Breast Cancer Res (2012) 0.89
The management of patients with polycystic ovary syndrome. Nat Rev Endocrinol (2014) 0.88
Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. J Diabetes Investig (2014) 0.88
Androgen concentrations in umbilical cord blood and their association with maternal, fetal and obstetric factors. PLoS One (2012) 0.88
Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging (2009) 0.87
Steroid profiling by gas chromatography-mass spectrometry and high performance liquid chromatography-mass spectrometry for adrenal diseases. Horm Cancer (2011) 0.87
Sex steroids and glucose metabolism. Asian J Androl (2014) 0.87
Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed) (2014) 0.86
Endogenous sex hormones, metabolic syndrome, and diabetes in men and women. Curr Cardiol Rep (2014) 0.85
Associations between salivary testosterone and cortisol levels and neonatal health and growth outcomes. Early Hum Dev (2012) 0.85
Mass spectrometry theory and application to adrenal diseases. Mol Cell Endocrinol (2013) 0.85
A review of the relationships between endogenous sex steroids and incident ischemic stroke and coronary heart disease events. Curr Cardiol Rev (2015) 0.85
Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? Hum Reprod (2008) 0.85
Measurement of androgen and estrogen concentrations in cord blood: accuracy, biological interpretation, and applications to understanding human behavioral development. Front Endocrinol (Lausanne) (2014) 0.85
A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians. Can Urol Assoc J (2010) 0.85
Validity of serum testosterone, free androgen index, and calculated free testosterone in women with suspected hyperandrogenism. Oman Med J (2012) 0.85
Current practices and challenges in the standardization and harmonization of clinical laboratory tests. Am J Clin Nutr (2016) 0.85
Measurement of estradiol, estrone, and testosterone in postmenopausal human serum by isotope dilution liquid chromatography tandem mass spectrometry without derivatization. Steroids (2015) 0.84
Acquired Hypogonadotropic Hypogonadism (AHH) in Thalassaemia Major Patients: An Underdiagnosed Condition? Mediterr J Hematol Infect Dis (2016) 0.84
The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev (2016) 0.83
Pharmacologically induced hypogonadism and sexual function in healthy young women and men. Neuropsychopharmacology (2008) 0.83
Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy. Steroids (2010) 0.83
Validity of estimating non-sex hormone-binding globulin bound testosterone and oestradiol from total hormone measurements in boys and girls. Ann Clin Biochem (2010) 0.83
FEM1A and FEM1B: novel candidate genes for polycystic ovary syndrome. Hum Reprod (2008) 0.83
The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update (2013) 0.82
Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry. PLoS One (2014) 0.82
Longitudinal development of hormone levels and grey matter density in 9 and 12-year-old twins. Behav Genet (2015) 0.81
Do evolutionary life-history trade-offs influence prostate cancer risk? a review of population variation in testosterone levels and prostate cancer disparities. Evol Appl (2012) 0.81
The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice. FASEB J (2014) 0.81
Andropause: Current concepts. Indian J Endocrinol Metab (2013) 0.81
The validity of androgen assays. Aging Male (2007) 0.81
Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists. Can Urol Assoc J (2013) 0.81
Endocrinology and physiology of pseudocyesis. Reprod Biol Endocrinol (2013) 0.81
Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis. Sci Rep (2016) 0.80
Partial androgen deficiency, depression, and testosterone supplementation in aging men. Int J Endocrinol (2012) 0.80
Diagnosis and management of testosterone deficiency. Asian J Androl (2015) 0.80
An update on male hypogonadism therapy. Expert Opin Pharmacother (2014) 0.80
Diagnosis and challenges of polycystic ovary syndrome in adolescence. Semin Reprod Med (2014) 0.79
Adolescent endogenous sex hormones and breast density in early adulthood. Breast Cancer Res (2015) 0.79
Steroid assays in paediatric endocrinology. J Clin Res Pediatr Endocrinol (2010) 0.79
Testosterone and bioavailable testosterone help to distinguish between mild Cushing's syndrome and polycystic ovarian syndrome. Horm Metab Res (2008) 0.79
Endocrine Dysfunction in Diamond-Blackfan Anemia (DBA): A Report from the DBA Registry (DBAR). Pediatr Blood Cancer (2015) 0.79
Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: the Framingham Heart Study. Int J Androl (2012) 0.79
Diagnosis and Treatment of Low Testosterone among Patients with End-Stage Renal Disease. Semin Dial (2014) 0.78
Circulating sex steroids and prostate cancer: introducing the time-dependency theory. World J Urol (2013) 0.78
Identification of late-onset hypogonadism in middle-aged and elderly men from a community of China. Asian J Androl (2016) 0.78
Androgen prevents hypogonadal bone loss via inhibition of resorption mediated by mature osteoblasts/osteocytes. Bone (2012) 0.78
Androgen resistance in squirrel monkeys (Saimiri spp.). Comp Med (2008) 0.78
A Positive Affective Neuroendocrinology Approach to Reward and Behavioral Dysregulation. Front Psychiatry (2015) 0.78
Persistent apparent pancreatic β-cell defects in premenarchal PCOS relatives. J Clin Endocrinol Metab (2014) 0.78
The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev (2010) 4.95
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med (2004) 4.50
The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol (2005) 3.85
Identification of ligands for DAF-12 that govern dauer formation and reproduction in C. elegans. Cell (2006) 3.82
Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2010) 3.80
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol (2011) 3.02
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A (2011) 2.89
An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension (2013) 2.72
Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet (2003) 2.36
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab (2011) 2.32
Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 2.28
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab (2012) 2.25
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension (2012) 2.23
Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab (2004) 2.22
Retracted Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab (2008) 2.21
Challenges to the measurement of estradiol: an endocrine society position statement. J Clin Endocrinol Metab (2013) 2.11
Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol (2008) 1.92
Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension (2011) 1.85
Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril (2005) 1.82
Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation (2003) 1.71
Cushing's Syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab (2006) 1.58
Arginine 276 controls the directional preference of AKR1C9 (rat liver 3alpha-hydroxysteroid dehydrogenase) in human embryonic kidney 293 cells. Endocrinology (2005) 1.58
Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension (2006) 1.57
Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab (2006) 1.56
Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril (2002) 1.55
Laparoscopic evaluation following failure to achieve pregnancy after ovulation induction with clomiphene citrate. Fertil Steril (2003) 1.51
Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet (2011) 1.51
The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. J Clin Endocrinol Metab (2013) 1.50
Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril (2008) 1.49
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab (2006) 1.49
Endocrine assessment of relative reproductive age in normal eumenorrheic younger and older women across multiple cycles. Am J Obstet Gynecol (2003) 1.44
Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 1.44
Salivary cortisol and the diagnosis of Cushing's syndrome: a coming of age. Endocrine (2012) 1.43
Reproductive hormone exposure timing and ischemic heart disease: Complicated answers to a simple question. Maturitas (2010) 1.39
Fifteen-year trend in the use of male reproductive surgery: analysis of the healthcare cost and utilization project data. BJU Int (2011) 1.39
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause (2012) 1.35
Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril (2005) 1.34
Socioeconomic and racial predictors of undergoing laparoscopic hysterectomy for selected benign diseases: analysis of 341487 hysterectomies. J Minim Invasive Gynecol (2008) 1.33
Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol (2006) 1.32
Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res (2012) 1.30
3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology (2010) 1.27
Identification of the nuclear receptor DAF-12 as a therapeutic target in parasitic nematodes. Proc Natl Acad Sci U S A (2009) 1.26
Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res (2013) 1.26
Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol (2005) 1.25
A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res (2013) 1.25
Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab (2012) 1.25
5alpha-androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving 5alpha-pregnane-3alpha,17alpha-diol-20-one as a key intermediate. Endocrinology (2003) 1.24
p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.24
Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol (2007) 1.23
The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab (2012) 1.23
Pregnancy hormone concentrations across ethnic groups: implications for later cancer risk. Cancer Epidemiol Biomarkers Prev (2005) 1.21
CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. J Biol Chem (2003) 1.21
Visually scoring hirsutism. Hum Reprod Update (2009) 1.21
A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS. Hum Mutat (2006) 1.20
The rise in adrenal androgen biosynthesis: adrenarche. Semin Reprod Med (2004) 1.20
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab (2006) 1.19
Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol (2004) 1.18
Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers (2004) 1.17
Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf) (2005) 1.17
Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) (2005) 1.17
Nonclassic congenital adrenal hyperplasia. Int J Pediatr Endocrinol (2010) 1.17
Two intronic mutations cause 17-hydroxylase deficiency by disrupting splice acceptor sites: direct demonstration of aberrant splicing and absent enzyme activity by expression of the entire CYP17 gene in HEK-293 cells. J Clin Endocrinol Metab (2004) 1.17
Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass. J Clin Psychiatry (2011) 1.17
miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes (2013) 1.17
FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One (2011) 1.16
Specifications for trueness and precision of a reference measurement system for serum/plasma 25-hydroxyvitamin D analysis. Clin Chim Acta (2009) 1.16
Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis. Endocr Pract (2009) 1.15
Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric (2012) 1.14
Human cytochrome b5 requires residues E48 and E49 to stimulate the 17,20-lyase activity of cytochrome P450c17. Biochemistry (2006) 1.13
Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab (2006) 1.13
Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J Clin Endocrinol Metab (2004) 1.12
Novel pathway of adipogenesis through cross-talk between adipose tissue macrophages, adipose stem cells and adipocytes: evidence of cell plasticity. PLoS One (2011) 1.12
Hyperthyroidism-associated coronary vasospasm with myocardial infarction and subsequent euthyroid angina. Thyroid (2008) 1.11
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) (2011) 1.10
Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril (2009) 1.10
Basic concepts and recent developments in human steroid hormone biosynthesis. Rev Endocr Metab Disord (2007) 1.10
The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord (2007) 1.09
New enzyme immunoassay for salivary cortisol. Clin Chem (2003) 1.09
The 17, 20-lyase activity of cytochrome p450c17 from human fetal testis favors the delta5 steroidogenic pathway. J Clin Endocrinol Metab (2003) 1.08
Diagnosis of polycystic ovary syndrome. Clin Obstet Gynecol (2007) 1.08
5alpha-reduced C21 steroids are substrates for human cytochrome P450c17. Arch Biochem Biophys (2003) 1.07
Menstrual cycle affects renal-adrenal and hemodynamic responses during prolonged standing in the postural orthostatic tachycardia syndrome. Hypertension (2010) 1.06
Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab (2008) 1.06
Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 1.06
Age-related analysis of inhibin A, inhibin B, and activin a relative to the intercycle monotropic follicle-stimulating hormone rise in normal ovulatory women. J Clin Endocrinol Metab (2004) 1.05
Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab (2010) 1.04
From the eye of the nurses: 360-degree evaluation of residents. J Contin Educ Health Prof (2009) 1.04
Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab (2009) 1.03
Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril (2006) 1.03
Congenital adrenal hyperplasia. J Pediatr Adolesc Gynecol (2011) 1.03
Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glands. Eur J Endocrinol (2011) 1.02
Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Endocr Relat Cancer (2008) 1.02
Cardiac blood biomarkers in patients receiving thoracic (chemo)radiation. Lung Cancer (2008) 1.02
Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis. J Clin Endocrinol Metab (2008) 1.02
Defining hirsutism in Chinese women: a cross-sectional study. Fertil Steril (2011) 1.01
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Fertil Steril (2012) 1.01
The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab (2004) 1.01